Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

- Millennium on track to file sNDA in first quarter 2008 -

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the interim analysis results of the large, international Phase III VISTA(1) trial in patients with newly diagnosed multiple myeloma showed that the therapy of VELCADE, melphalan and prednisone (VMP) demonstrated a highly statistically significant improvement in all efficacy measures, including time-to-disease progression, complete remission rate, progression-free survival and overall survival, compared to melphalan and prednisone (MP) alone. Based on the recommendation of an independent data monitoring committee (IDMC), which conducted the planned interim, the control arm of the trial was stopped early to allow patients still being treated with MP to have VELCADE added to their therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"These results position VELCADE based therapy as a new standard of care for newly diagnosed multiple myeloma patients," said Paul Richardson, M.D., Associate Professor of Medicine, Harvard Medical School; Clinical Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston; and a lead investigator of the VISTA trial. "The combination of VELCADE with melphalan and prednisone surpassed all efficacy endpoints, including time-to-disease progression, complete remission rate, progression-free survival and overall survival, and did so, much earlier than expected. We are excited at the possibility this new therapy could be available to our patients sooner."

In the first
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 A lot of discussion in the medical community ... illnesses, injuries, or conditions. As medical science advances, doctors and ... ones that they consider to be more cutting edge. Yet, ... textbook method of treatment that stands out as the best ...
(Date:1/23/2015)...  The Partnership to Fight Chronic Disease (PFCD) released a public opinion ... a new study analyzing the impact of increased cost sharing on ... working to educate policy makers and the public on the costs ... on how the Iowa healthcare exchange could ...
(Date:1/23/2015)... 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW ... for operable and inoperable solid tumor cancers, announced today that ... th Annual Phacilitate Immunotherapy Forum in Washington ... will take place on January 26 at 10:30 a.m. EST ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... WESTLAKE VILLAGE, Calif., Dec. 21 Specialists On ... its 10,000th emergency teleneurology consultation since the company,s inception. ... expands SOC,s leadership position as the largest private emergency ... consults when it recently responded to a neurologic emergency ...
... , SAN MARINO, Calif., Dec. 21 /PRNewswire-FirstCall/ -- ... announced that it filed an updated Information Statement including ... September 30, 2009, as well as year-end statements for ... in PDF form free of charge via the ...
Cached Medicine Technology:Specialists On Call Delivers 10,000th Emergency Teleneurology Consultation 2Specialists On Call Delivers 10,000th Emergency Teleneurology Consultation 3Viral Genetics Files 2009 3rd Quarter Consolidated Financials and Information Statement at Pinksheets.com 2
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... Inc. (Nasdaq: CYNO ), a leading developer ... treatment systems, announced today that the United States District ... favorable set of rulings in a Markman hearing in ... alleges that CoolTouch,s 1320 nm CoolLipo(TM) laser system infringes ...
... to Combat Waste in Medicare ProgramsSEATTLE, March 3 ... for the Centers for Medicare & Medicaid Services (CMS), ... Care Guidelines (R). HDI will use the ... claims. HDI is the RAC for 17 Western states ...
... CORAL GABLES, Fla., March 3 Catalyst Pharmaceutical Partners, ... that acquires or in-licenses, develops and commercializes prescription drugs ... to its previously announced product development program. In ... Catalyst has decided to halt enrollment of new subjects ...
... Supported by a Grant from Otsuka America Pharmaceutical, Inc.ROCKVILLE, ... has named three universities as the recipients of Helping ... of up to $5,000 for a community mental health ... the supervision of medical faculty. The awards are ...
... chain honored for accomplishments , ... Dallas (Vocus) March 3, 2009 -- ... Alliance of Greater Cincinnati, was recently announced 2008 Contracting Professional of the ... ,Described as a pioneer in healthcare for more than three decades, Robb ...
... quality of life among obese men are related to ... gastric bypass surgery according to a new study accepted ... Clinical Endocrinology & Metabolism (JCEM). , "Previous studies ... count and can be associated with infertility, but we ...
Cached Medicine News:Health News:Cynosure Obtains Favorable Markman Rulings in Patent Infringement Case Against CoolTouch 2Health News:Cynosure Obtains Favorable Markman Rulings in Patent Infringement Case Against CoolTouch 3Health News:Recovery Audit Contractor HealthDataInsights Licenses Milliman Care Guidelines(R) 2Health News:Recovery Audit Contractor HealthDataInsights Licenses Milliman Care Guidelines(R) 3Health News:Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction 2Health News:Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction 3Health News:American Psychiatric Foundation Announces Recipients of Helping Hands Grants 2Health News:American Psychiatric Foundation Announces Recipients of Helping Hands Grants 3Health News:The Health Alliance's Dennis Robb Announced Contracting Professional of the Year by The Journal of Healthcare Contracting 2Health News:The Health Alliance's Dennis Robb Announced Contracting Professional of the Year by The Journal of Healthcare Contracting 3Health News:The Health Alliance's Dennis Robb Announced Contracting Professional of the Year by The Journal of Healthcare Contracting 4
... Operation: , Standby: All toggle switches at off ... pulse/s); 10 s (1 pulses/10 s) , Tetanus: ... pulses/s) , Train-Of-Four: Single (4 pulses/2 s); repeat ... Output Current: Adjustable from 0-70 mA(HI range) 0-6.0mA ...
... of Operation: , Double Burst : 2 60-ms bursts ... 1 s (1 pulse/s) , Tetanus: 50 Hz ... Train-Of-Four: Single (4 pulses/2 s) , Output Current: Adjustable ... Monophasic pulses (200-us duration) , Indicators: Battery LED (green) ...
... Modes of Operation: , Standby: A standby ... stimulus pulses. , Twitch: 1 s (1 pulse/s) ... Train-Of-Four: Single (4 pulses/2 s) , Output Current: ... Square Wave Monophasic pulses (200-us duration) , Indicators: ...
Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...
Medicine Products: